Targeting MDM2-mediated suppression of p53 with idasanutlin: a promising therapeutic approach for acute lymphoblastic leukemia [0.03%]
靶向MDM2介导的p53抑制作用：用于急性淋巴细胞白血病治疗的idasanutlin方法的前景不容小觑
Seyda Gungordu,Erhan Aptullahoglu
Seyda Gungordu
Despite available treatments for acute lymphoblastic leukemia (ALL), the disease's high clinical variability necessitates new therapeutic strategies, particularly for patients with high-risk features. The tumor suppressor protein p53, encod...
A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors [0.03%]
一项Ⅰb期研究：MK-8353联合派姆单抗治疗晚期实体瘤患者的安全性、药代动力学和抗肿瘤活性研究
Nehal J Lakhani,Howard Burris rd,Wilson H Miller Jr et al.
Nehal J Lakhani et al.
Combining a checkpoint inhibitor with an inhibitor of extracellular signal-regulated kinase (ERK) may result in synergistic antitumor activity. We evaluated MK-8353, an ERK1 and ERK2 inhibitor, plus pembrolizumab in a phase 1b study in pati...
Clinical characteristics, treatment, and outcomes of nivolumab induced immune thrombocytopenia [0.03%]
纳武单抗致免疫性血小板减少症的临床特征、治疗和转归分析
Liping Peng,Zhaoquan Wu,Wei Sun et al.
Liping Peng et al.
Immune thrombocytopenia (ITP) represents an uncommon hematological side effect associated with nivolumab, and its distinct clinical attributes remain poorly defined. This research aimed to explore the clinical manifestations and outcomes of...
Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancer [0.03%]
ESK981多激酶抑制剂II期临床试验治疗转移性去势抵抗性前列腺癌患者
Elisabeth I Heath,Wei Chen,Lance Heilbrun et al.
Elisabeth I Heath et al.
ESK981 is a potent tyrosine kinase and PIKfyve lipid kinase inhibitor. This phase II trial evaluated the efficacy of ESK981 as a single agent in patients with androgen receptor-positive (AR +) metastatic castration-resistant prostate cancer...
Retraction Note: The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells [0.03%]
撤回 notice:Kinesin Eg5 抑制剂 K858 诱导乳腺癌细胞凋亡但也会引起 survivin 相关的化疗抗性
Francesca De Iuliis,Ludovica Taglieri,Gerardo Salerno et al.
Francesca De Iuliis et al.
Retraction of Publication
Investigational new drugs. 2024 Oct;42(5):601. DOI:10.1007/s10637-024-01469-5 2024
Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma [0.03%]
先前免疫检查点抑制剂治疗后进展的不可切除肝细胞癌患者接受度伐鲁单抗联合曲美木单抗治疗的疗效响应
Nami Mori,Nobuharu Tamaki,Shintaro Takaki et al.
Nami Mori et al.
Although immune checkpoint inhibitors (ICI) are used for unresectable hepatocellular carcinoma (HCC), it is unclear whether sequential ICI treatment-durvalumab plus tremelimumab (DT) after progression on atezolizumab plus bevacizumab (AB)-i...
Multicenter Study
Investigational new drugs. 2024 Oct;42(5):559-565. DOI:10.1007/s10637-024-01470-y 2024
Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer [0.03%]
一项关于sitravatinib联合免疫治疗靶向多种受体酪氨酸激酶的Ib期研究：晚期肾细胞癌和去势抵抗性前列腺癌患者
Shubham Pant,Byoung Chul Cho,Christos E Kyriakopoulos et al.
Shubham Pant et al.
Sitravatinib (MGCD516) is an oral inhibitor of several closely related oncogenic tyrosine kinase receptors that include VEGFR-2 (vascular endothelial growth factor receptor-2), AXL, and MET (mesenchymal-epithelial transition). The safety an...
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort [0.03%]
高PD-L1表达晚期非小细胞肺癌免疫检查点抑制剂治疗应答深度及疗效的探索性分析：多中心回顾性队列研究
Yusuke Tachibana,Kenji Morimoto,Tadaaki Yamada et al.
Yusuke Tachibana et al.
The association between depth of response (DpR) and treatment outcomes has been documented across various types of cancer. Immune checkpoint inhibitor (ICI)-based treatment is globally used as first-line treatment for non-small cell lung ca...
Multicenter Study
Investigational new drugs. 2024 Oct;42(5):538-546. DOI:10.1007/s10637-024-01467-7 2024
Yenisetti Rajendra Prasad,J Anakha,Snehal Sainath Jawalekar et al.
Yenisetti Rajendra Prasad et al.
The rapid increase in cancer cases worldwide necessitates the development of novel therapeutic approaches. Therapies targeting cancer's altered metabolism, especially those that deplete critical amino acids, have emerged as promising ones, ...
Design optimization of Fucoidan-coating Cationic Liposomes for enhance Gemcitabine delivery [0.03%]
基于壳多糖和岩藻糖的阳离子脂质体递药系统的构建及优化增强吉西他滨抗胰腺癌作用研究
Epiphane K Silli,Zhenjiang Zheng,Xintao Zhou et al.
Epiphane K Silli et al.
Obstacles facing chemotherapeutic drugs for cancers led scientists to load Gemcitabine (GEM) into nanocarriers like liposomes, known for their nontoxicity profile and targeting capacity. The liposomal nanostructures containing GEM were coat...